| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/03/2023 | 179.3% | Roth MKM | $12.5 → $12.75 | Maintains | Buy |
| 10/10/2023 | 31.43% | JP Morgan | $12 → $6 | Maintains | Underweight |
| 10/05/2023 | 119.06% | Northland Capital Markets | $17.5 → $10 | Maintains | Outperform |
| 10/05/2023 | 173.82% | Roth MKM | $25 → $12.5 | Maintains | Buy |
| 10/05/2023 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 10/05/2023 | 162.87% | Raymond James | $15 → $12 | Maintains | Outperform |
| 10/05/2023 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
| 08/02/2023 | 283.35% | Northland Capital Markets | $22.5 → $17.5 | Maintains | Outperform |
| 08/02/2023 | 228.59% | Oppenheimer | $25 → $15 | Maintains | Outperform |
| 08/02/2023 | 228.59% | Raymond James | $24 → $15 | Maintains | Outperform |
| 08/02/2023 | 272.4% | JMP Securities | $45 → $17 | Maintains | Outperform |
| 08/02/2023 | 162.87% | JP Morgan | $17 → $12 | Downgrades | Neutral → Underweight |
| 05/09/2023 | 885.76% | JMP Securities | → $45 | Reiterates | → Market Outperform |
| 05/09/2023 | 425.74% | Raymond James | $25 → $24 | Maintains | Outperform |
| 04/19/2023 | 338.12% | JP Morgan | $24 → $20 | Maintains | Neutral |
| 02/21/2023 | 447.65% | Oppenheimer | $23 → $25 | Maintains | Outperform |
| 02/17/2023 | 447.65% | Oppenheimer | $23 → $25 | Maintains | Outperform |
| 02/17/2023 | 447.65% | Raymond James | $26 → $25 | Maintains | Outperform |
| 12/20/2022 | 425.74% | JP Morgan | $26 → $24 | Maintains | Neutral |
| 11/15/2022 | 469.55% | Raymond James | $29 → $26 | Downgrades | Strong Buy → Outperform |
| 07/14/2022 | 272.4% | JP Morgan | $18 → $17 | Maintains | Neutral |
| 05/06/2022 | 666.7% | Raymond James | $43 → $35 | Maintains | Strong Buy |
| 05/06/2022 | 403.83% | Oppenheimer | $28 → $23 | Maintains | Outperform |
| 04/14/2022 | 381.93% | Goldman Sachs | $47 → $22 | Maintains | Buy |
| 04/14/2022 | — | Barrington Research | Downgrades | Outperform → Market Perform | |
| 04/14/2022 | 885.76% | JMP Securities | $60 → $45 | Maintains | Market Outperform |
| 03/04/2022 | 447.65% | Jefferies | $38 → $25 | Downgrades | Buy → Hold |
| 02/22/2022 | 600.99% | JP Morgan | $27 → $32 | Maintains | Neutral |
| 02/18/2022 | 841.95% | Raymond James | $35 → $43 | Maintains | Strong Buy |
| 01/28/2022 | 666.7% | Raymond James | → $35 | Upgrades | Market Perform → Strong Buy |
| 12/13/2021 | 557.17% | JP Morgan | $49 → $30 | Downgrades | Overweight → Neutral |
| 10/22/2021 | 1214.35% | JMP Securities | $70 → $60 | Maintains | Market Outperform |
| 08/10/2021 | — | Vertical Research | Downgrades | Buy → Neutral | |
| 06/23/2021 | 1542.94% | Barrington Research | → $75 | Initiates Coverage On | → Outperform |
| 05/07/2021 | 1521.03% | Goldman Sachs | $67 → $74 | Maintains | Buy |
| 04/28/2021 | 1433.41% | JMP Securities | $47 → $70 | Maintains | Market Outperform |
| 02/01/2021 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 01/26/2021 | 995.29% | Jefferies | → $50 | Initiates Coverage On | → Buy |
| 12/08/2020 | 666.7% | Roth Capital | $29 → $35 | Maintains | Buy |
| 11/06/2020 | 447.65% | Raymond James | $20 → $25 | Maintains | Outperform |
| 10/26/2020 | 513.36% | JMP Securities | $19 → $28 | Maintains | Market Outperform |
| 10/01/2020 | 403.83% | Northland Capital Markets | → $23 | Initiates Coverage On | → Outperform |
| 08/12/2020 | 217.63% | Raymond James | $9 → $14.5 | Maintains | Outperform |
| 06/16/2020 | 97.15% | JP Morgan | $7 → $9 | Upgrades | Neutral → Overweight |
| 04/22/2020 | 75.25% | JP Morgan | → $8 | Downgrades | Overweight → Neutral |
| 12/27/2019 | 97.15% | Raymond James | $9.5 → $9 | Maintains | Outperform |
| 07/22/2019 | — | Oppenheimer | Initiates Coverage On | → Outperform | |
| 07/22/2019 | 294.3% | JP Morgan | → $18 | Initiates Coverage On | → Overweight |
| 07/22/2019 | 173.82% | Raymond James | → $12.5 | Initiates Coverage On | → Outperform |
| 07/22/2019 | 162.87% | Deutsche Bank | → $12 | Initiates Coverage On | → Hold |
| 07/22/2019 | 140.96% | Goldman Sachs | → $11 | Initiates Coverage On | → Neutral |
What is the target price for Cambium Networks (CMBM)?
The latest price target for Cambium Networks (NASDAQ: CMBM) was reported by Roth MKM on November 3, 2023. The analyst firm set a price target for $12.75 expecting CMBM to rise to within 12 months (a possible 179.30% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cambium Networks (CMBM)?
The latest analyst rating for Cambium Networks (NASDAQ: CMBM) was provided by Roth MKM, and Cambium Networks maintained their buy rating.
When is the next analyst rating going to be posted or updated for Cambium Networks (CMBM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cambium Networks, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cambium Networks was filed on November 3, 2023 so you should expect the next rating to be made available sometime around November 3, 2024.
Is the Analyst Rating Cambium Networks (CMBM) correct?
While ratings are subjective and will change, the latest Cambium Networks (CMBM) rating was a maintained with a price target of $12.50 to $12.75. The current price Cambium Networks (CMBM) is trading at is $4.57, which is out of the analyst's predicted range.